Crititech Overview

  • Founded
  • 1997
Founded
  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • Debt - PPP
  • Investors
  • 8

Crititech General Information

Description

Manufacturer of fine-particle compounds designed to micronize a wide variety of small-molecule and biotechnology drugs. The company's fine-particle compounds utilizes its proprietary CO2 technology to develop potent molecules, poorly soluble compounds and bio-molecules with its ability to simplify formulations, enabling pharmacists to develop and manufacture unique and differentiated drugs and medical devices.

Contact Information

Website
www.crititech.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
  • 1849 East 1450 Road
  • Lawrence, KS 66044
  • United States
+1 (785) 000-0000

Crititech Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Crititech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Debt - PPP 29-Apr-2020 000.00 Completed Generating Revenue
7. Accelerator/Incubator 01-Apr-2019 00.00 000.00 Completed Generating Revenue
6. Later Stage VC 21-Aug-2014 00.000 00.000 Completed Generating Revenue
5. Debt - General 10-Dec-2009 00.000 00.000 Completed Generating Revenue
4. Later Stage VC 02-Dec-2008 00000 00000 Completed Generating Revenue
3. Later Stage VC 15-Feb-2005 00000 00000 Completed Generating Revenue
2. Grant 04-Aug-2004 $100K Completed Generating Revenue
1. Early Stage VC 01-Aug-2002 Completed Generating Revenue
To view Crititech’s complete valuation and funding history, request access »

Crititech Executive Team (10)

Name Title Board Seat Contact Info
Matthew McClorey JD President & Board Member
Michael Baltezor Ph.D Chief Scientific Officer
Jahna Espinosa Director, Laboratory Operations
Mark Williams Vice President, Technical Operations
You’re viewing 4 of 10 executive team members. Get the full list »

Crititech Board Members (6)

Name Representing Role Since
Bala Subramaniam Ph.D Crititech Founder & Board Member 000 0000
Matthew McClorey JD Crititech President & Board Member 000 0000
Sam Campbell Crititech Chairman 000 0000
William Duncan Ph.D Self Board Member 000 0000
You’re viewing 4 of 6 board members. Get the full list »

Crititech Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Crititech Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Accelerate Venture Partners Angel Group Minority 000 0000 000000 0
SeedStep Angels Angel Group Minority 000 0000 000000 0
Tony Schmidt Angel (individual) Minority 000 0000 000000 0
KTECH Capital Venture Capital Minority 000 0000 000000 0
Precede Fund Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Crititech Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 (00000000 01-Jan-2017 0000 00000 000 Drug Discovery
NanOlogy (Pharmaceutical) 01-Jan-2015 Joint Venture Drug Discovery
To view Crititech’s complete investments history, request access »

Ready to get started?

Request a free trial